View Full Version : Straterra Approved in Canada!


Tara
01-06-05, 11:04 PM
Non-stimulant approved in Canada for attention-deficit disorder

Last Updated Thu, 06 Jan 2005 18:11:30 EST CBC News (http://www.cbc.ca/news/credit.html)


TORONTO - Health Canada has approved a new, non-stimulant drug for the treatment of ADHD, or attention-deficit hyperactivity disorder. Children with ADHD are usually treated with Ritalin, a powerful stimulant that helps the brain control behaviour. Ritalin allows children to concentrate on tasks they find difficult or boring, such as reading and writing.






FROM CBC MANITOBA: Ritalin on the Rise (http://winnipeg.cbc.ca/archives/ritalin/index2.html)


The new drug, called Atomoxetine, failed trials as an anti-depressant but has found new life as a treatment for ADHD.

Health Canada's approval means the drug will be commercially available across the country for those over the age of six, under the brand name Strattera, by the end of March 2005.






FROM FEB. 26, 2003: New drug to control attention deficit disorder (http://www.cbc.ca/story/news/national/2003/02/26/Consumers/ADHDdrug_030226.html)


Strattera is a non-stimulant option for ADHD patients. It is the first in a new class of ADHD drugs that selectively block the re-uptake of a chemical messenger in the brain called norepinephrine.

The medication is taken once a day and works around the clock, according to child psychiatrists.

Eli Lilly and Company's Strattera has been approved and on the market in the U.S. since 2002.

Last month, the U.S. Food and Drug Administration warned doctors and patients of serious liver problems associated with Strattera following two reports of liver injury, one in a teenager and one in an adult.



The FDA now requires a bolded warning on Strattera labels to alert people to look for signs and symptoms of liver problems, including:

Itchy skin.
Jaundice (yellowing of the skin or whites of the eyes).
Dark urine.
Upper right-sided abdominal tenderness.
Unexplained "flu-like" symptoms.


Health Canada also plans to issue a public advisory once the drug is released.

ADHD affects three to seven per cent of school-aged children, according to the American Psychiatric Association.

In Canada, the total number of prescriptions written for Ritalin and Ritalin-related drugs in 2003 was nearly 1.5 million.


From http://www.cbc.ca/story/science/national/2005/01/06/ADHD-Strattera050106.html